METHOD OF DIAGNOSTICS OF ORAL CAVITY DYSBIOSIS IN PATIENTS WITH METABOLIC SYNDROME OR TYPE 2 DIABETES MELLITUS Russian patent published in 2024 - IPC G01N33/50 A61B5/00 

FIELD: medicine; therapeutic dentistry; laboratory diagnostics.

SUBSTANCE: invention concerns the diagnosis of oral dysbiosis in patients with metabolic syndrome or type 2 diabetes. In the oral fluid, the level of glucose, urease activity, ammonia concentration, pH state and free radical oxidation are determined. In the oral microbiota — the number of yeast fungi of Candida genus and urease-positive microorganisms. With glucose level of 0.18 mmol/l, urease activity value of 2.011 mcmol⋅min^-1 per mg of protein, ammonia level of 0.084 mmol, pH 6.1, luminescence sum 22.36 u/e, urease-positive Staphylococcus spp. and Enterobacteriaceae spp. in an amount of 104 CFU/unit in the mouth, gram-positive facultative anaerobic rods Lactobacillus spp. in an amount of 104 CFU/unit and opportunistic yeast-like fungi of Candida genus in yeast form in an amount of 103-4 CFU/unit oral dysbiosis is diagnosed against the background of metabolic syndrome. With glucose level of 0.34 mmol/l, urease activity value of 2.678 mcmol⋅⋅min^-1 per mg of protein, ammonia level of 0.139 mmol, pH 6.5, luminescence sum 16.6 u/e in the mouth, urease-positive Staphylococcus spp. and Enterobacteriaceae spp. in an amount of 105 CFU/unit, gram-positive facultative anaerobic rods Lactobacillus spp. in an amount of 105 CFU/unit and opportunistic yeast-like fungi of Candida genus in yeast form in an amount of 104-5 CFU/unit oral dysbiosis is diagnosed against the background of type 2 diabetes mellitus.

EFFECT: use of the invention improves prediction accuracy.

1 cl, 2 ex, 1 tbl